Hodgkins Lymphoma, Lymphoproliferative Disorder, Non-Hodgkins Lymphoma
Conditions
Keywords
cellular therapy, lymphoma, lymphoproliferative disorder
Brief summary
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will be feasible ( able to be done), safe and well tolerated (no unexpected serious events will occur). In addition, potential donors who are EBV positive will be enrolled to donate peripheral blood to help build a bank of these specific EBV fighting cell lines.
Interventions
DRUGEBV CTL's
Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
OTHERPeripheral Blood Donor
Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
Sponsors
Children's National Research Institute
Baylor College of Medicine
M.D. Anderson Cancer Center
University of Michigan
University of Utah
City of Hope Medical Center
Ohio University
Johns Hopkins University
New York Medical College
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Patient must be at least 1 year of age. Patient or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human Services. Patients should have been off other investigational therapy for one month prior to entry in this study. Patient must have adequate organ function as below: Adequate renal function defined as: * Serum creatinine \<2.0 x normal, or * Creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or \>60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range Adequate liver function defined as: * Total bilirubin \<2.0 x normal; and * SGOT (AST) or SGPT (ALT) \<5.0 x normal Adequate pulmonary function defined as: \- Pulse oximetry \>94% in room air. Lansky (\< 16yr) or Karnofsky (\> 16 yrs) performance status ≥ 50% Life expenctancy ≥ 6 weeks. Women of child bearing age require a negative urine pregnancy test. Clinical status at enrollment to allow tapering of steroids to less than 0.5mg/kg/day prednisone at time of treatment. 4.5 Disease Status (Eligibility) 4.5.1 Any patient, with one or more of the following EBV-positive type II latency or associated disorders, regardless of the histological subtype: Hodgkin lymphoma Non-Hodgkin lymphoma Lymphoproliferative disorder Severe chronic active EBV infection syndrome (SCAEBV), defined as high EBV viral load in plasma or PBMC (\> 4000 genomes per μg PBMC DNA) and/or biopsy tissue positive for EBV The disease needs to be in one of the following stages: At diagnosis who would be unable to receive conventional chemotherapy or in first relapse AND the patient is not a candidate for HSCT Partial response after conventional therapy. Refractory to conventional therapy for his/her condition. In second or subsequent relapse. Residual disease after autologous, syngeneic or allogeneic HSCT. All patients entered into the study ideally will have tumor tissue from the original diagnostic specimen and/or relapse reviewed centrally for confirmation of EBV positive disease. If no specimen is available, local pathology report documenting EBV positivity is acceptable. Appropriate immunophenotyping to confirm the diagnosis will be performed. In addition, in situ hybridization for EBV (LMP1, and/or EBER positivity) will be performed. All central morphologic analysis and immunohistochemical/insitu hybridization staining will be performed in the laboratory of Sherrie Perkins and Rodney Miles at the University of Utah. Donor Eligibility for LMP-CTL Third Party Banking (Aim 2.1.2) * Donor must be HIV negative. * Donors must have adequate hematopoietic function defined as absolute neutrophil count \> 1000/mm3, hemoglobin \> 10 g/dl, and platelet count \>50,000/mm3 and be EBV IgG seropositive. * Donors will have peripheral blood collected for LMP specific CTL production. A minimum of 60 cc of peripheral blood x 2 for a total maximum amount of blood of 120cc, will be collected from the donor (subjects must be at least 12 kg or 24 pounds). (See Appendix B) For donors \<18 years a maximum of 3cc/kg blood will be taken in an 8 week period. * For donors that are to undergo stem cell collection, the peripheral blood for LMP specific CTL production will be collected prior to the stem cell collection and without a specific day specification. * Donor eligibility must meet criteria as per 21 CFR 1271.
Exclusion criteria
Currently receiving any investigational agents or have received any tumor vaccines within previous 4 weeks. Active acute grade III-IV graft-versus-host disease. Severe refractory intercurrent infection other than EBV. Received alemtuzumab or other anti-Tcell antibody within 28 days. HIV seropositivity. Pregnancy (due to unknown effects of this therapy on a fetus) or lactation. Patients with PTLD post solid organ transplantation eligible for the COG PTLD LMP/CTL protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the safety of giving 3rd party EBV-CTLs | 1 year | Patients will be monitored for any unexpected adverse events related to investigational product. |
| To develop a third party bank of LMP-specific CTL | on going | EBV positive donors will be asked to provide an extra sample of peripheral blood to build a donor bank of EBV-CTLs for this protocol and future use. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To measure the response rate | 1 year | patients will be followed a year following administration of cells for disease response. |
Countries
United States
Outcome results
None listed